TNF and congestive heart failure: Therapeutic possibilities

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 3, 2004, Pages 203-209

  Müller Ehmsen, Jochen ^a   Schwinger, Robert H G ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cytokines; Heart failure; Neurohormones; TNF

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; INFLIXIMAB; NEUROHORMONE; PENTOXIFYLLINE; PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANALYTICAL ERROR; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; MORTALITY; PATHOGENESIS; QUALITY OF LIFE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042799388     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.3.203     Document Type: Review

References (55)

1. COHN JN, LEVINE TB, OLIVARI MT et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. (1984) 311(13):819-823.
2. MANN DL, KENT RL, PARSONS B, COOPER G IV: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation (1992) 85(2):790-804.
3. HELIN K, STOLL M, MEFFERT S, STROTH U, UNGER T. The role of angiotensin receptors in cardiovascular diseases. Ann. Med. (1997) 29(1):23-29.
4. HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation (2001) 104(24):2996-3007.
5. LEVINE B, KALMAN J, MAYER L, FILLIT HM, PACKER M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. (1990) 323(4):236-241.
6. KAPADIA S, LEE J, TORRE-AMIONE, G, BIRDSALL HH, MA TS, MANN DL: Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. (1995) 96(2):1042-1052.
7. MANN DL: Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu. Rev. Physiol. (2003) 65:81-101.
8. PALMIERI EA, BENINCASA G, DI RELLA F et al.: Differential expression of TNF-α, IL-6, and IGF-1 by graded mechanical sum in normal rat myocardium. Am. J. Physiol. Heart Circ. Physiol. (2002) 282(3):H926-H934.
9. BAUMGARTEN G, KNUEFERMANN P, KALRA D et al.: Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation (2002) 105(18):2192-2197.
10. BRASIER AR, JAMALUDDIN M, HAN Y, PATTERSON C, RUNGE MS: Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-κB (NF-κB) transcription factor. Mol. Cell. Biochem. (2000) 212(1-2):155-169.
11. TRACEY KJ, BEUTLER B, LOWRY SF et al.: Shock and tissue injury induced by recombinant human cachectin. Science (1986) 234(4775):470-474.
12. BOZKURT B, KRIBBS SB, CLUBB FJ Jr et al.: Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation (1998) 97(14):1382-1391.
13. PAGANI FD, BAKER LS, HSI C, KNOX M, FINK MP, VISNER MS: Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J. Clin. Invest. (1992) 90(2):389-398.
14. MURRAY DR, FREEMAN GL: Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs. Circ. Res. (1996) 78(1):154-160.
15. KUBOTA T, MCTIERNAN CF, FRYE CS et al.: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ. Res. (1997) 81(4):627-635.
16. DIBBS ZI, DIWAN A, NEMOTO S et al.: Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation (2003) 108(8):1002-1008.
17. KURRELMEYER KM, MICHAEL LH, BAUMGARTEN G et al.: Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc. Natl. Acad. Sci. USA (2000) 97(10):5456-5461.
18. MISRA A, HAUDEK SB, KNUEFERMANN P et al.: Nuclear factor-κB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation (2003) 108(25):3075-3078.
19. TORRE-AMIONE G, KAPADIA S, LEE J, BIES RD, LEBOVITZ R, MANN DL: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation (1995) 92(6):1487-1493.
20. MANN DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. (2002) 91(11):988-998.
21. ORAL H, DORN GW, MANN DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J. Biol. Chem. (1997) 272(8):4836-4842.
22. 2+ transients. FEBS Lett. (1995 ) 376(1-2):24-30.
23. GULICK T, CHUNG MK, PIEPER SJ, LANGE LG, SCHREINER GF: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc. Natl. Acad. Sci. USA (1989) 86(17):6753-6757.
24. KROWN KA, PAGE MT, NGUYEN C et al.: Tumor necrosis factor α-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest. (1996) 98(12):2854-2865.
25. YOKOYAMA T, NAKANO M, BEDNARCZYK JL, MCINTYRE BW, ENTMAN M, MANN DL; Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation (1997) 95(5):1247-1252.
26. LI YY, FENG YQ, KADOKAMI T et al.: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. Proc. Natl. Acad. Sci. USA (2000) 97(23):12746-12751.
27. SETA Y, SHAN K, BOZKURT B, ORAL H, MANN DL: Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. (1996) 2(3):243-249.
28. DESWAL A, PETERSEN NJ, FELDMAN AM, YOUNG JB, WHITE BG, MANN DL: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation (2001) 103(16):2055-2059.
29. TORRE-AMIONE G, KAPADIA S, BENEDICT C, ORAL H, YOUNG JB, MANN DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. (1996) 27(5):1201-1206.
30. AUKRUST P, UELAND T, LIEN E et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1999) 83(3):376-382.
31. FRANCIS GS, BENEDICT C, JOHNSTONE DE et al.: Comparison of neuroendocrine activation in patients with left ventricular dyfunction with and without congestive heart failure. A substudy ofthe Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82:1724-1729.
32. WEI GC, SIROIS MG, QU R, LIU P, ROULEAU JL: Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat. J. Cardiovasc. Pharmacol. (2002) 39(6):842-850.
33. GULLESTAD L, AUKRUST P, UELAND T et al.: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol. (1999) 34(7):2061-2067.
34. GURLEK A. KILICKAP M, DINCER I, DANDACHI R, TUTKAK H, ORAL D: Effect of losartan on circulating TNFα, levels and left ventricular systolic performance in patients with heart failure. J. Cardiovasc. Risk (2001) 8(5):279-282.
35. PRABHU SD, CHANDRASEKAR B, MURRAY DR, FREEMAN GL: β-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation (2000) 101(17):2103-2109.
36. MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001-2007.
37. TSUTAMOTO T, WADA A. MATSUMOTO T et al.: Relationship between tumor necrosis factor-α production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. (2001) 37(8):2086-2092.
38. SLIWA K, SKUDICKY D, CANDY G, WISENBAUGH T, SARELI P: Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet (1998) 351(9109):1091-1093.
39. AGOSTON I, DIBBS ZI, WANG F et al.: Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J. Card. Fail. (2002) 8(5):306-314.
40. GULLESTAD L, SEMB AG, HOLT E et al.: Effect of thalidomide in patients with chronic heart failure. Am. Heart J. (2002) 144(5):847-850.
41. SLIWA K, WOODIWISS A, KONE VN et al.: Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation (2004) 109(6):750-755.
42. KAPADIA S, TORRE-AMIONE G, YOKOYAMA T, MANN DL: Soluble TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro. Am. J. Physiol. (1995) 268(2 Pt 2):H517-H525.
43. DESWAL A, BOZKURT B, SETA Y et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99fs(25):3224-3226.
44. BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation (2001) 103(8):1044-1047.
45. ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance: of the results of RECOVER. RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. (2002) 86(2-3):123-130.
46. COLETTA AP, CLARK AL, BANARJEE P, CLELAND JG: Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur. J. Heart Fail. (2002) 4(4):559-561.
47. CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107(25):3133-3140.
48. HOFBAUER KH, SCHOOF E, KURTZ A, SANDNER P: Inflammatory cytokines stimulate adrenomedulin expression through nitric oxide-dependent and -independent pathways. Hypertension (2002) 39(1):161-167.
49. KATZ SD, RAO R, BERMAN JW et al.: Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Cinculation (1994) 90(1):12-16.
50. WONG GH, GOEDDEL DV: Induction of manganous superoxide dismutase by tumor necrosis factor. possible protective mechanism. Science (1988) 242(4880):941-944.
51. COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345(23):1667-1675.
52. PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349(20):1893-1906.
53. PACKER M, CALIFF RM, KONSTAM MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106(8):920-926.
54. DUNSELMAN P, HJALMARSON A, KJEKSHUS J, MCMURRAY J, WAAGSTEIN F: The statin wars. Lancet (2003) 362(9398):185. Discussion 1856.
55. GULLESTAD L, AASS H, FJELD JG et al.: Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation (2001) 103(2):220-225.